Scholarlink

Background <p>Metabolic abnormalities play a pivotal role in the pathogenesis of amyotrophic lateral sclerosis (ALS). Metabolic syndrome (MetS), a cluster of metabolic disorders, is highly prevalent among the elderly. However, the association between MetS and clinical characteristics, disease progression, and survival in ALS remains unclear.</p> Methods <p>We included 529 ALS patients and collected demographic, clinical, and hematological data, including blood glucose, HbA1c, and lipid profiles. Patients were followed longitudinally. MetS was defined according to the criteria of the Chinese Diabetes Society. Multivariate logistic regression, Kaplan–Meier survival analysis, and Cox proportional hazards models were used to analyze.</p> Results <p>Compared to ALS patients without MetS, those with MetS had higher proportion of lower limb onset (44.3% vs. 24.6%, <i>P &lt;</i> 0.001), and a faster disease progression rate (0.60 vs. 0.55, <i>P</i> = 0.022). After adjusting for confounders, MetS and hypertension were significantly associated with fast disease progression (OR = 1.808, 95% CI: 1.048–3.120, <i>P</i> = 0.033; OR = 2.615, 95% CI: 1.358–5.035, <i>P</i> = 0.004), and remained significant after multiple correction. Interaction analysis revealed significant interactions between glucose intolerance and dyslipidemia (<i>P</i> = 0.038), and between glucose intolerance and BMI (<i>P</i> = 0.040), but lost significance after multiple correction. There was no significant difference in survival between ALS patients with and without MetS. After adjusting for confounders, there was no significant association between MetS and the risk of death.</p> Conclusion <p>MetS, particularly in the presence of hypertension, was associated with fast disease progression in ALS, though not with survival. These suggest metabolic dysfunction may influence ALS progression and warrant further investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between metabolic syndrome, its individual components and progression of amyotrophic lateral sclerosis

  • 期刊论文

  • 发表日期：

    2025年9月19日

查看全文
  • Qirui Jiang,
  • Qianqian Wei,
  • Tianmi Yang,
  • Junyu Lin,
  • Yi Xiao,
  • Chunyu Li,
  • Lingyu Zhang,
  • Yanbing Hou,
  • Ruwei Ou,
  • Shichan Wang,
  • Jiyong Liu,
  • Yan Liang,
  • Huifang Shang

摘要

Background

Metabolic abnormalities play a pivotal role in the pathogenesis of amyotrophic lateral sclerosis (ALS). Metabolic syndrome (MetS), a cluster of metabolic disorders, is highly prevalent among the elderly. However, the association between MetS and clinical characteristics, disease progression, and survival in ALS remains unclear.

Methods

We included 529 ALS patients and collected demographic, clinical, and hematological data, including blood glucose, HbA1c, and lipid profiles. Patients were followed longitudinally. MetS was defined according to the criteria of the Chinese Diabetes Society. Multivariate logistic regression, Kaplan–Meier survival analysis, and Cox proportional hazards models were used to analyze.

Results

Compared to ALS patients without MetS, those with MetS had higher proportion of lower limb onset (44.3% vs. 24.6%, P < 0.001), and a faster disease progression rate (0.60 vs. 0.55, P = 0.022). After adjusting for confounders, MetS and hypertension were significantly associated with fast disease progression (OR = 1.808, 95% CI: 1.048–3.120, P = 0.033; OR = 2.615, 95% CI: 1.358–5.035, P = 0.004), and remained significant after multiple correction. Interaction analysis revealed significant interactions between glucose intolerance and dyslipidemia (P = 0.038), and between glucose intolerance and BMI (P = 0.040), but lost significance after multiple correction. There was no significant difference in survival between ALS patients with and without MetS. After adjusting for confounders, there was no significant association between MetS and the risk of death.

Conclusion

MetS, particularly in the presence of hypertension, was associated with fast disease progression in ALS, though not with survival. These suggest metabolic dysfunction may influence ALS progression and warrant further investigation.